Novel Fusion Protein Targeting Mitochondrial DNA Improves Pancreatic Islet Functional Potency and Islet Transplantation Outcomes
Open Access
- 1 November 2017
- journal article
- research article
- Published by SAGE Publications in Cell Transplantation
- Vol. 26 (11) , 1742-1754
Abstract
Long-term graft survival is an ongoing challenge in the field of islet transplantation. With the growing demand for transplantable organs, therapies to improve organ quality and reduce the incidence of graft dysfunction are of paramount importance. We evaluated the protective role of a recombinant DNA repair protein targeted to mitochondria (Exscien I-III), as a therapeutic agent using a rodent model of pancreatic islet transplantation. We first investigated the effect of therapy on isolated rat islets cultured with pro-inflammatory cytokines (interleukin-1 β, interferon γ, and tumor necrosis factor α) for 48 h and documented a significant reduction in apoptosis by flow cytometry, improved viability by immunofluorescence, and conserved functional potency in vitro and in vivo in Exscien I-III-treated islets. We then tested the effect of therapy in systemic inflammation using a rat model of donor brain death (BD) sustained for a 6-h period. Donor rats were allocated to 4 groups: (non-BD + vehicle, non-BD + Exscien I-III, BD + vehicle, and BD + Exscien I-III) and treated with Exscien I-III (4 mg/kg) or vehicle 30 min after BD induction. Sham (non-BD)-operated animals receiving either Exscien I-III or vehicle served as controls. Islets purified from BD + Exscien I-III-treated donors showed a significant increase in glucose-stimulated insulin release in vitro when compared to islets from vehicle-treated counterparts. In addition, donor treatment with Exscien I-III attenuated the effects of BD and significantly improved the functional potency of transplanted islets in vivo. Our data indicate that mitochondrially targeted antioxidant therapy is a novel strategy to protect pancreas and islet quality from the deleterious effects of cytokines in culture and during the inflammatory response associated with donation after BD. The potential for rapid translation into clinical practice makes Exscien I-III an attractive therapeutic option for the management of brain-dead donors or as an additive to islets in culture after isolation setting.Keywords
Funding Information
- National Institutes of Health (T32 training grant (J. Danobeitia) T32AI125231, ES03456)
- American Society of Transplant Surgeons (Scientist Scholarship (J. Danobeitia))
This publication has 63 references indexed in Scilit:
- Islet transplantation for Type 1 diabetes: where are we now?Expert Review of Clinical Immunology, 2014
- Alleviation of Instant Blood-Mediated Inflammatory Reaction in Autologous Conditions Through Treatment of Human Islets with NF-κB InhibitorsTransplantation, 2014
- Brain Death–Induced Inflammatory Activity in Human Pancreatic TissueTransplantation, 2014
- Multicenter Analysis of Novel and Established Variables Associated with Successful Human Islet Isolation OutcomesAmerican Journal of Transplantation, 2010
- Systemic inflammation in the brain‐dead organ donorActa Anaesthesiologica Scandinavica, 2009
- Early Events in Kidney Donation: Progression of Endothelial Activation, Oxidative Stress and Tubular Injury After Brain DeathAmerican Journal of Transplantation, 2008
- Neutrophilic granulocytes are the predominant cell type infiltrating pancreatic islets in contact with ABO-compatible bloodClinical and Experimental Immunology, 2005
- Organ donation and utilization in the USAAmerican Journal of Transplantation, 2004
- Brain Death Impairs Pancreatic MicrocirculationAmerican Journal of Transplantation, 2004
- Brain Death Significantly Reduces Isolated Pancreatic Islet Yields and Functionality In Vitro and In Vivo After Transplantation in RatsDiabetes, 2003